Research programme: nanobodies - Ablynx/Novo Nordisk

Drug Profile

Research programme: nanobodies - Ablynx/Novo Nordisk

Latest Information Update: 05 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx
  • Developer Ablynx; Novo Nordisk
  • Class Antibodies; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 25 Nov 2015 Early research in Undefined indication in Belgium (Parenteral)
  • 25 Nov 2015 Ablynx and Novo Nordisk enter into a global exclusive collaboration and licensing agreement to discover and develop novel Nanobody® drug candidates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top